- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Median enhances cancer lesion software
Median Technologies has updated its Median LMS (Lesion Management Solution) software toevaluate, follow and report on changes involving of cancerous lesions seen on CT images from the neck to the pelvis.
Median Technologies has updated its Median LMS (Lesion Management Solution) software to
evaluate, follow and report on changes involving of cancerous lesions seen on CT images from the neck to the pelvis. The enhanced software, slated to debut at RSNA 2009, generates a single report for the quantitative management of patient response to therapy, according to the company. It is designed for routine clinical use, as well as in multicenter clinical trials. Median LMS automates the initial evaluation and follow-up of cancerous lesions identified in CT images of the thorax, abdomen and pelvis, automatically generating a standardized oncologic report and centralizing all lesion information. In so doing, it helps in the assessment of patient response to therapy, assisting in an evaluation of the effectiveness drugs. This can be especially important in clinical trials, when experimental drugs require standardized measurement and reporting of target lesion response, according to the company.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
